在持续推进产品落地升级、夯实行业领先市占率的基础上，华大智造领先布局生命科学前沿核心技术， 持续巩固全球生命科技领域第一梯队优势地位。近期，华大智造官宣拟收购时空组学与纳米孔测序两大 前沿技术平台，进阶为全球唯一覆盖"全读长测序+空间组学"全链条产品矩阵的生命科技上游企业。 CycloneSEQ纳米孔测序技术在单芯片通量、甲基化直测等方面已比肩国际龙头ONT，Stereo-seq时空组 学技术在捕获面积、分辨率、多级别分析能力上也显著优于10X Genomics的同类产品。此次收购实施 后，华大智造将成为中国版的"illumina+ONT+10X Genomics"，在全球高端市场的技术竞争力将进一步 凸显。 智通财经APP获悉，2月27日盘后，华大智造(688114.SH)发布2025年度业绩快报，公司全年实现营业收 入27.80亿元，并实现大幅减亏。报告期内，公司归母净利润为-2.37亿元，亏损同比收窄60.57%;扣非归 母净利润为-3.78亿元，亏损同比收窄42.11%。公司持续推进"提质增效重回报"系列举措，包括人效提 升、研发聚焦、营销费用全周期管理等措施，期间费用(不含财务费用)同比下降约19% ...

Core Viewpoint - The acquisition of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xifeng Technology Co., Ltd. by BGI Genomics is a strategic move to enhance its product offerings in the field of genomics, making it the only company globally to cover the entire chain of "long-read sequencing + spatial omics" technologies [1][2][3] Group 1: Acquisition Details - BGI Genomics announced a cash acquisition of 100% equity in both companies for approximately 366 million yuan [1] - The acquisition aims to integrate cutting-edge technologies, including Stereo-seq and CycloneSEQ, into BGI Genomics' existing product matrix [2][3] Group 2: Technological Integration - The integration of Stereo-seq and CycloneSEQ technologies will create a comprehensive technical chain that enhances BGI Genomics' competitive edge [2] - Stereo-seq technology is recognized for its international leadership in resolution and field of view, while CycloneSEQ offers unique advantages in long-read sequencing and real-time capabilities [3] Group 3: Strategic Positioning - This acquisition strengthens BGI Genomics' first-mover advantage in the AI medical field and brain-computer interface technology [4] - The company is positioned to lead in multiple cutting-edge sectors by leveraging its advanced technologies [4] Group 4: Financial Aspects - The acquisition is strategically timed to capitalize on the valuation window, allowing BGI Genomics to acquire assets at a more favorable price before they become commercially mature [5] - The estimated valuations for the acquired companies are significantly lower than comparable industry players, reducing financial pressure on BGI Genomics [5][6] Group 5: Risk Mitigation and Growth Potential - The acquisition includes performance guarantees from the sellers, providing a safety net for BGI Genomics and protecting shareholder interests [6] - The integration of new revenue streams from the acquired technologies is expected to enhance the company's overall revenue and profitability [6][7] Group 6: Industry Context - The acquisition aligns with the trend of deep mergers and acquisitions in the industry, reflecting a focus on strategic integration and value creation [7] - BGI Genomics' move serves as a model for similar industry consolidations, emphasizing the importance of building competitive barriers through comprehensive technology offerings [7]